APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tuberculosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchTuberculosis Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Tuberculosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Tuberculosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tuberculosis Drugs include Abbott, Teva Pharmaceutical Industries Ltd, Sanofi, Johnson & Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc, AstraZeneca Plc and Viatris Inc. (Mylan N.V.), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Drugs Segment by Company

Abbott

Teva Pharmaceutical Industries Ltd

Sanofi

Johnson & Johnson

Novartis AG

Eli Lilly and Company

Pfizer Inc

AstraZeneca Plc

Viatris Inc. (Mylan N.V.)

Sun Pharmaceutical Industries Ltd.

Otsuka Pharmaceutical

Macleods Pharmaceuticals Ltd.

Lupin Laboratories Ltd

FRESENIUS SE & Co. KGaA (Fresenius Kabi)

Cipla Ltd

Cadila Pharmaceuticals

ANI Pharmaceuticals, Inc

Alkem Laboratories Ltd

Tuberculosis Drugs Segment by Type

First Line Drugs Therapy

Combination Drugs Therapy

Second Line Drugs Therapy

Tuberculosis Drugs Segment by Application

Hospital

Private Clinic

Others

Tuberculosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tuberculosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tuberculosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tuberculosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Drugs Industry Trends Table 2. Tuberculosis Drugs Industry Drivers Table 3. Tuberculosis Drugs Industry Opportunities and Challenges Table 4. Tuberculosis Drugs Industry Restraints Table 5. Global Tuberculosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tuberculosis Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Tuberculosis Drugs Sales Market Share by Manufacturers Table 9. Global Tuberculosis Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Tuberculosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tuberculosis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tuberculosis Drugs Manufacturers, Product Type & Application Table 13. Global Tuberculosis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of First Line Drugs Therapy Table 17. Major Manufacturers of Combination Drugs Therapy Table 18. Major Manufacturers of Second Line Drugs Therapy Table 19. Global Tuberculosis Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Tuberculosis Drugs Sales by Type (2021-2026) & (k units) Table 21. Global Tuberculosis Drugs Sales by Type (2027-2032) & (k units) Table 22. Global Tuberculosis Drugs Sales Market Share by Type (2021-2026) Table 23. Global Tuberculosis Drugs Sales Market Share by Type (2027-2032) Table 24. Global Tuberculosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Tuberculosis Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global Tuberculosis Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global Tuberculosis Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Tuberculosis Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Private Clinic Table 31. Major Manufacturers of Others Table 32. Global Tuberculosis Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Tuberculosis Drugs Sales by Application (2021-2026) & (k units) Table 34. Global Tuberculosis Drugs Sales by Application (2027-2032) & (k units) Table 35. Global Tuberculosis Drugs Sales Market Share by Application (2021-2026) Table 36. Global Tuberculosis Drugs Sales Market Share by Application (2027-2032) Table 37. Global Tuberculosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Tuberculosis Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global Tuberculosis Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global Tuberculosis Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Tuberculosis Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Tuberculosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Tuberculosis Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Tuberculosis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Tuberculosis Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Tuberculosis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Tuberculosis Drugs Sales by Country (2021-2026) & (k units) Table 49. North America Tuberculosis Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Tuberculosis Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe Tuberculosis Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Tuberculosis Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Tuberculosis Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Tuberculosis Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Tuberculosis Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Tuberculosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Tuberculosis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Tuberculosis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Tuberculosis Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Tuberculosis Drugs Revenue Market Share by Region (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Abbott Tuberculosis Drugs Product Portfolio Table 68. Abbott Recent Development Table 69. Teva Pharmaceutical Industries Ltd Company Information Table 70. Teva Pharmaceutical Industries Ltd Business Overview Table 71. Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio Table 73. Teva Pharmaceutical Industries Ltd Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Tuberculosis Drugs Product Portfolio Table 78. Sanofi Recent Development Table 79. Johnson & Johnson Company Information Table 80. Johnson & Johnson Business Overview Table 81. Johnson & Johnson Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Johnson & Johnson Tuberculosis Drugs Product Portfolio Table 83. Johnson & Johnson Recent Development Table 84. Novartis AG Company Information Table 85. Novartis AG Business Overview Table 86. Novartis AG Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Novartis AG Tuberculosis Drugs Product Portfolio Table 88. Novartis AG Recent Development Table 89. Eli Lilly and Company Company Information Table 90. Eli Lilly and Company Business Overview Table 91. Eli Lilly and Company Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Eli Lilly and Company Tuberculosis Drugs Product Portfolio Table 93. Eli Lilly and Company Recent Development Table 94. Pfizer Inc Company Information Table 95. Pfizer Inc Business Overview Table 96. Pfizer Inc Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Pfizer Inc Tuberculosis Drugs Product Portfolio Table 98. Pfizer Inc Recent Development Table 99. AstraZeneca Plc Company Information Table 100. AstraZeneca Plc Business Overview Table 101. AstraZeneca Plc Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. AstraZeneca Plc Tuberculosis Drugs Product Portfolio Table 103. AstraZeneca Plc Recent Development Table 104. Viatris Inc. (Mylan N.V.) Company Information Table 105. Viatris Inc. (Mylan N.V.) Business Overview Table 106. Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio Table 108. Viatris Inc. (Mylan N.V.) Recent Development Table 109. Sun Pharmaceutical Industries Ltd. Company Information Table 110. Sun Pharmaceutical Industries Ltd. Business Overview Table 111. Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio Table 113. Sun Pharmaceutical Industries Ltd. Recent Development Table 114. Otsuka Pharmaceutical Company Information Table 115. Otsuka Pharmaceutical Business Overview Table 116. Otsuka Pharmaceutical Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio Table 118. Otsuka Pharmaceutical Recent Development Table 119. Macleods Pharmaceuticals Ltd. Company Information Table 120. Macleods Pharmaceuticals Ltd. Business Overview Table 121. Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio Table 123. Macleods Pharmaceuticals Ltd. Recent Development Table 124. Lupin Laboratories Ltd Company Information Table 125. Lupin Laboratories Ltd Business Overview Table 126. Lupin Laboratories Ltd Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio Table 128. Lupin Laboratories Ltd Recent Development Table 129. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information Table 130. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview Table 131. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio Table 133. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Development Table 134. Cipla Ltd Company Information Table 135. Cipla Ltd Business Overview Table 136. Cipla Ltd Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Cipla Ltd Tuberculosis Drugs Product Portfolio Table 138. Cipla Ltd Recent Development Table 139. Cadila Pharmaceuticals Company Information Table 140. Cadila Pharmaceuticals Business Overview Table 141. Cadila Pharmaceuticals Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio Table 143. Cadila Pharmaceuticals Recent Development Table 144. ANI Pharmaceuticals, Inc Company Information Table 145. ANI Pharmaceuticals, Inc Business Overview Table 146. ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio Table 148. ANI Pharmaceuticals, Inc Recent Development Table 149. Alkem Laboratories Ltd Company Information Table 150. Alkem Laboratories Ltd Business Overview Table 151. Alkem Laboratories Ltd Tuberculosis Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio Table 153. Alkem Laboratories Ltd Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Tuberculosis Drugs Distributors List Table 157. Tuberculosis Drugs Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Tuberculosis Drugs Product Image Figure 2. Global Tuberculosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Drugs Sales (2021-2032) & (k units) Figure 5. Global Tuberculosis Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tuberculosis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. First Line Drugs Therapy Image Figure 9. Combination Drugs Therapy Image Figure 10. Second Line Drugs Therapy Image Figure 11. Global Tuberculosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Tuberculosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Tuberculosis Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Tuberculosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Tuberculosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Tuberculosis Drugs Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Private Clinic Image Figure 19. Others Image Figure 20. Global Tuberculosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Tuberculosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Tuberculosis Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Tuberculosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Tuberculosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Tuberculosis Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Tuberculosis Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Tuberculosis Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Tuberculosis Drugs Sales Market Share by Country (2021-2032) Figure 40. China Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Tuberculosis Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Tuberculosis Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Tuberculosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Tuberculosis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Tuberculosis Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Tuberculosis Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Tuberculosis Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Tuberculosis Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Tuberculosis Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Tuberculosis Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • First Line Drugs Therapy
  • Combination Drugs Therapy
  • Second Line Drugs Therapy
Applications
  • Hospital
  • Private Clinic
  • Others
Companies covered
  • Abbott
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • AstraZeneca Plc
  • Viatris Inc. (Mylan N.V.)
  • Sun Pharmaceutical Industries Ltd.
  • Otsuka Pharmaceutical
  • Macleods Pharmaceuticals Ltd.
  • Lupin Laboratories Ltd
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • Cipla Ltd
  • Cadila Pharmaceuticals
  • ANI Pharmaceuticals, Inc
  • Alkem Laboratories Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tuberculosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tuberculosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tuberculosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tuberculosis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tuberculosis Drugs Market Dynamics
  1. 2.1 Tuberculosis Drugs Industry Trends
  2. 2.2 Tuberculosis Drugs Industry Drivers
  3. 2.3 Tuberculosis Drugs Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Drugs Industry Restraints
3 Tuberculosis Drugs Market by Manufacturers
  1. 3.1 Global Tuberculosis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tuberculosis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tuberculosis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tuberculosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tuberculosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tuberculosis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Tuberculosis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tuberculosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tuberculosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tuberculosis Drugs Tier 1, Tier 2, and Tier 3
4 Tuberculosis Drugs Market by Type
  1. 4.1 Tuberculosis Drugs Type Introduction
  2. 4.1.1 First Line Drugs Therapy
  3. 4.1.2 Combination Drugs Therapy
  4. 4.1.3 Second Line Drugs Therapy
  5. 4.2 Global Tuberculosis Drugs Sales by Type
  6. 4.2.1 Global Tuberculosis Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Tuberculosis Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Tuberculosis Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Tuberculosis Drugs Revenue by Type
  10. 4.3.1 Global Tuberculosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Tuberculosis Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Tuberculosis Drugs Revenue Market Share by Type (2021-2032)
5 Tuberculosis Drugs Market by Application
  1. 5.1 Tuberculosis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Private Clinic
  4. 5.1.3 Others
  5. 5.2 Global Tuberculosis Drugs Sales by Application
  6. 5.2.1 Global Tuberculosis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Drugs Revenue by Application
  10. 5.3.1 Global Tuberculosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Drugs Revenue Market Share by Application (2021-2032)
6 Global Tuberculosis Drugs Sales by Region
  1. 6.1 Global Tuberculosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Tuberculosis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tuberculosis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tuberculosis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tuberculosis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tuberculosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tuberculosis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tuberculosis Drugs Revenue by Region
  1. 7.1 Global Tuberculosis Drugs Revenue by Region
  2. 7.1.1 Global Tuberculosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tuberculosis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Tuberculosis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Tuberculosis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tuberculosis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tuberculosis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tuberculosis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tuberculosis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tuberculosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Tuberculosis Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Teva Pharmaceutical Industries Ltd
  8. 8.2.1 Teva Pharmaceutical Industries Ltd Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Ltd Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Ltd Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Tuberculosis Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Tuberculosis Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Tuberculosis Drugs Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Tuberculosis Drugs Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Tuberculosis Drugs Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 AstraZeneca Plc
  44. 8.8.1 AstraZeneca Plc Company Information
  45. 8.8.2 AstraZeneca Plc Business Overview
  46. 8.8.3 AstraZeneca Plc Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Plc Tuberculosis Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Plc Recent Developments
  49. 8.9 Viatris Inc. (Mylan N.V.)
  50. 8.9.1 Viatris Inc. (Mylan N.V.) Company Information
  51. 8.9.2 Viatris Inc. (Mylan N.V.) Business Overview
  52. 8.9.3 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio
  54. 8.9.5 Viatris Inc. (Mylan N.V.) Recent Developments
  55. 8.10 Sun Pharmaceutical Industries Ltd.
  56. 8.10.1 Sun Pharmaceutical Industries Ltd. Company Information
  57. 8.10.2 Sun Pharmaceutical Industries Ltd. Business Overview
  58. 8.10.3 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio
  60. 8.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  61. 8.11 Otsuka Pharmaceutical
  62. 8.11.1 Otsuka Pharmaceutical Company Information
  63. 8.11.2 Otsuka Pharmaceutical Business Overview
  64. 8.11.3 Otsuka Pharmaceutical Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio
  66. 8.11.5 Otsuka Pharmaceutical Recent Developments
  67. 8.12 Macleods Pharmaceuticals Ltd.
  68. 8.12.1 Macleods Pharmaceuticals Ltd. Company Information
  69. 8.12.2 Macleods Pharmaceuticals Ltd. Business Overview
  70. 8.12.3 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio
  72. 8.12.5 Macleods Pharmaceuticals Ltd. Recent Developments
  73. 8.13 Lupin Laboratories Ltd
  74. 8.13.1 Lupin Laboratories Ltd Company Information
  75. 8.13.2 Lupin Laboratories Ltd Business Overview
  76. 8.13.3 Lupin Laboratories Ltd Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio
  78. 8.13.5 Lupin Laboratories Ltd Recent Developments
  79. 8.14 FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  80. 8.14.1 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information
  81. 8.14.2 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview
  82. 8.14.3 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio
  84. 8.14.5 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Developments
  85. 8.15 Cipla Ltd
  86. 8.15.1 Cipla Ltd Company Information
  87. 8.15.2 Cipla Ltd Business Overview
  88. 8.15.3 Cipla Ltd Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cipla Ltd Tuberculosis Drugs Product Portfolio
  90. 8.15.5 Cipla Ltd Recent Developments
  91. 8.16 Cadila Pharmaceuticals
  92. 8.16.1 Cadila Pharmaceuticals Company Information
  93. 8.16.2 Cadila Pharmaceuticals Business Overview
  94. 8.16.3 Cadila Pharmaceuticals Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio
  96. 8.16.5 Cadila Pharmaceuticals Recent Developments
  97. 8.17 ANI Pharmaceuticals, Inc
  98. 8.17.1 ANI Pharmaceuticals, Inc Company Information
  99. 8.17.2 ANI Pharmaceuticals, Inc Business Overview
  100. 8.17.3 ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio
  102. 8.17.5 ANI Pharmaceuticals, Inc Recent Developments
  103. 8.18 Alkem Laboratories Ltd
  104. 8.18.1 Alkem Laboratories Ltd Company Information
  105. 8.18.2 Alkem Laboratories Ltd Business Overview
  106. 8.18.3 Alkem Laboratories Ltd Tuberculosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio
  108. 8.18.5 Alkem Laboratories Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Drugs Value Chain Analysis
  2. 9.1.1 Tuberculosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Drugs Production Mode & Process
  6. 9.2 Tuberculosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Drugs Distributors
  9. 9.2.3 Tuberculosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst